Reducing Adolescent Suicide Risk: Safety, Efficacy, and Connectome Phenotypes of Intravenous Ketamine
Status:
Not yet recruiting
Trial end date:
2025-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine if intravenous ketamine reduces suicidal thinking
compared to an active placebo (midazolam) in adolescents who have treatment resistant
depression and a recent history of a suicide event (defined as a suicide attempt, emergency
room evaluation for suicidal thinking, or a transition to inpatient care for suicidality in
the past 120 days).
The primary objective of this study is to determine whether ketamine reduces suicidal
ideation (as measured via the C-SSRS, recent ideation scale) relative to an active control,
midazolam, 48-hours after first administration in adolescents with TRD at high suicide risk.